PTCT vs TPVG Stock Comparison: AI Score, Valuation, Performance and Upside
PTCT (PTC Therapeutics) and TPVG (TriplePoint Venture Growth) are unrelated businesses — PTC is a rare disease biopharmaceutical company with Skyclarys (Friedreich's ataxia), Emflaza (DMD), and international Translarna revenues, while TPVG is a BDC providing venture debt to VC-backed companies and paying high dividend income. PTC appeals to biotech investors seeking rare disease pipeline value; TPVG appeals to income investors seeking 8-12% dividend yields.
PTCT vs TPVG is rare disease biopharmaceutical with first-in-class Friedreich's ataxia treatment and RNA platform pipeline (PTC Therapeutics' Skyclarys commercial launch, Emflaza DMD revenue, and long-running Translarna international business — navigating FDA regulatory challenges and rare disease competition) versus high-yield venture debt BDC paying 8-12% dividends (TriplePoint Venture Growth's loan portfolio to VC-backed life sciences and tech companies — earning interest income and warrant upside while accepting venture default risk) — biopharmaceutical capital appreciation versus specialty finance income.
TPVG holds the edge across 3 of 5 key metrics in this comparison. TPVG leads on both 1-year return (+1.25%) and forward P/E quality (5.64x vs 28.72x for PTCT), a relatively favorable combination of momentum and valuation. On fundamentals, PTCT is growing revenue faster (101.50%), while TPVG maintains the higher operating margin (76.32%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for PTCT (+38.30%) than for TPVG (+26.81%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Believe Skyclarys (Friedreich's ataxia) launch success will establish PTC as a multi-product rare disease company with a substantially larger U.S. revenue base
- See PTC's RNA-targeting scientific platform as generating multiple future rare genetic disease pipeline opportunities
- Are willing to accept binary clinical milestones and Translarna FDA rejection risk in exchange for rare disease exposure at a potentially below-NAV valuation
- Seek high current dividend income (8-12% yield) from a specialty venture lender with life sciences and technology expertise
- Believe TriplePoint's top-tier VC firm relationships provide access to high-quality borrowers with lower-than-average default rates
- Want equity-upside participation in venture-backed company success through the warrant component alongside fixed income from loan interest payments
| Metric | PTCT | TPVG |
|---|---|---|
| AI scorei | 63.6 | 33.6 |
| AI ranki | #109 | #2955 |
| Latest closei | $60.88 | $4.60 |
| 1M returni | -4.07% | -6.12% |
| 3M returni | -10.62% | +4.65% |
| 6M returni | -7.04% | -9.20% |
| 1Y returni | -10.88% | +1.25% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | PTCT | TPVG |
|---|---|---|
| 1Y ago | $8.96K (-10.4%) started 2025-11-03 | $12.14K (+21.4%) started 2025-11-03 |
| 5Y ago | $14.92K (+49.2%) started 2021-11-03 | $16.84K (+68.4%) started 2021-11-03 |
| 10Y ago | $145.3K (+1353.0%) started 2016-11-03 | $234.28K (+2242.8%) started 2016-11-03 |
Hypothetical — past performance does not guarantee future results.
| Metric | PTCT | TPVG |
|---|---|---|
| Market capi | $5.99B | $187.26M |
| Trailing P/Ei | N/A | 4.65 |
| Forward P/Ei | 28.72 | 5.64 |
| Price/Salesi | N/A | 2.09 |
| EV/Revenuei | 6.62 | 6.87 |
| Analyst targeti | $99.29 | $5.83 |
| Target upsidei | +38.30% | +26.81% |
| Metric | PTCT | TPVG |
|---|---|---|
| Revenue growthi | 101.50% | -5.20% |
| Earnings growthi | N/A | -19.80% |
| EPS growthi | N/A | -19.80% |
| FCF margini | -28.43% | +19.55% |
| Operating margini | 41.32% | 76.32% |
| Profit margini | -3.81% | 44.90% |
| ROIC proxyi | N/A | 11.45% |
| Return on equityi | N/A | 11.45% |
| Dividend yieldi | N/A | 28.70% |
| Payout ratioi | 0.00% | 94.95% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.55 | 1.43 |
| Debt/equityi | N/A | 125.89 |
| Current ratioi | 3.39 | 2.11 |
| Quick ratioi | 3.20 | 1.21 |
Over the past year, PTCT and TPVG have moved barely in the same direction (correlation of 0.05), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | PTCT | TPVG |
|---|---|---|---|
| 1Y | Growthi | -10.38% | -0.39% |
| CAGRi | -10.41% | -0.39% | |
| Volatilityi | 41.46% | 34.76% | |
| Sharpe ratioi | -0.17 | 0.03 | |
| Sortino ratioi | -0.24 | 0.05 | |
| Max drawdowni | 33.85% | 29.97% | |
| Current drawdowni | 32.02% | 20.73% | |
| Avg drawdowni | 16.87% | 14.37% | |
| Ulcer Indexi | 18.90% | 16.59% | |
| Max daily dropi | 9.94% | 5.98% | |
| Max wkly dropi | 12.49% | 11.72% | |
| 5Y | Growthi | +49.22% | -43.52% |
| CAGRi | +8.34% | -10.80% | |
| Volatilityi | 55.10% | 32.56% | |
| Sharpe ratioi | 0.34 | -0.33 | |
| Sortino ratioi | 0.50 | -0.44 | |
| Max drawdowni | 69.42% | 54.79% | |
| Current drawdowni | 32.02% | 48.83% | |
| Avg drawdowni | 23.99% | 33.10% | |
| Ulcer Indexi | 29.55% | 35.26% | |
| Max daily dropi | 29.77% | 12.33% | |
| Max wkly dropi | 39.59% | 17.71% | |
| 10Y | Growthi | +1352.98% | +65.23% |
| CAGRi | +30.70% | +5.15% | |
| Volatilityi | 62.59% | 68.01% | |
| Sharpe ratioi | 0.65 | 0.24 | |
| Sortino ratioi | 1.05 | 0.53 | |
| Max drawdowni | 73.78% | 81.78% | |
| Current drawdowni | 32.02% | 48.83% | |
| Avg drawdowni | 26.83% | 21.19% | |
| Ulcer Indexi | 31.99% | 27.32% | |
| Max daily dropi | 30.58% | 45.49% | |
| Max wkly dropi | 39.59% | 71.51% |
| Category | PTCT | TPVG |
|---|---|---|
| Company | PTC Therapeutics, Inc. | TriplePoint Venture Growth BDC Corp. |
| Sector | Healthcare | Financial Services - Business Development Company / Venture Debt |
| Industry | Biotechnology | Asset Management |
| Core business | PTC Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Products include Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy (DMD) — approved in the EU but not the U.S.; Emflaza (deflazacort) for Duchenne muscular dystrophy — approved in the U.S.; Skyclarys (omaveloxolone) — the first FDA-approved treatment for Friedreich's ataxia (approved February 2023); and pipeline candidates for alpha-1 antitrypsin deficiency and other rare conditions. PTC's scientific platform focuses on post-transcriptional regulatory mechanisms (splicing, nonsense mutation readthrough) that enable RNA-targeting therapeutic approaches. | TriplePoint Venture Growth BDC is a specialty finance company (Business Development Company) providing venture lending — secured loans, equipment financing, and revolving credit facilities — to growth-stage companies that have raised venture capital. TPVG's borrowers are VC-backed startups and growth companies in life sciences and technology seeking non-dilutive capital between equity funding rounds. TPVG earns interest income on its loan portfolio and charges origination fees; as a BDC, TPVG distributes substantially all income to shareholders as dividends, typically yielding 8-12% annually. |
| Investor focus | Investors track PTC's revenue from its commercial portfolio (particularly Skyclarys launch trajectory), clinical pipeline milestones, cash burn and runway, and prospects for U.S. Translarna approval (repeatedly rejected by FDA; approved in EU). | Investors track TPVG's net investment income (NII) per share, portfolio credit quality (default losses on venture loans), end-of-term payments and prepayments, and net asset value (NAV) per share. |
- Skyclarys (Friedreich's ataxia) is the first FDA-approved treatment for FA — positioning PTC as the commercial leader in a disease with no prior approved therapy; orphan drug pricing and 7-year exclusivity provide strong economic protection
- Multiple commercial products provide revenue foundation — Translarna (ex-U.S.) and Emflaza (U.S.) generate ongoing cash flow reducing binary pipeline dependency
- Friedreich's ataxia patient community is highly motivated and organized, supporting reimbursement advocacy — the FA patient community has been waiting decades for an approved therapy; strong patient advocacy supports payer coverage decisions
- Venture debt provides high current income with equity upside through warrants — loan interest rates of 10-14% plus warrants in borrowers; if borrowers succeed and go public or are acquired, warrant value adds to returns
- BDC pass-through structure provides tax transparency and high dividend yield — TPVG distributes nearly all income as dividends; historically 8-12% yield attractive for income-focused investors
- Life sciences and technology expertise aligns TPVG with high-quality VC dealflow — TriplePoint Capital's deep VC relationships provide access to top-tier venture-backed borrowers with lower-than-average default rates
- Translarna has faced repeated FDA rejection for U.S. approval — U.S. approval would dramatically expand the addressable market but regulatory pathway has been elusive after multiple attempts
- Rare disease competition is intensifying as large biotechs and gene therapy companies target DMD — Sarepta Therapeutics has exon-skipping therapies and gene therapy for DMD; commercial competition limits Emflaza's market position
- Cash burn from pipeline development and Skyclarys commercial launch requires financing discipline — PTC is not yet fully self-funding; continued investment in launch activities requires careful cash management
- Venture-backed company defaults are the primary credit risk — if borrowers fail (startup fails, VC backing stops), TPVG may recover less than loan value from secured collateral; default rates depend on the macro environment and VC funding availability
- Interest rate environment affects BDC returns and valuations — rising rates increase TPVG's borrowing costs; falling rates reduce income on floating-rate loans and depress dividends
- External management structure creates potential conflicts of interest — TriplePoint Capital manages TPVG and earns management fees; the structure may not always align manager incentives with TPVG shareholder interests
Compare more than two at a time
This page is a fixed writeup on PTCT and TPVG. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside PTCT and TPVG, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.